These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 25703419)

  • 81. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial.
    Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.
    Ristorto J; Messas N; Marchandot B; Kibler M; Hess S; Meyer N; Schaeffer M; Tuzin N; Ohlmann P; Jesel L; Morel O
    J Atheroscler Thromb; 2018 Aug; 25(8):674-689. PubMed ID: 29415954
    [TBL] [Abstract][Full Text] [Related]  

  • 83. "Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States.
    Larmore C; Effron MB; Molife C; DeKoven M; Zhu Y; Lu J; Karkare S; Lieu HD; Lee WC; Vetrovec GW
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):535-544. PubMed ID: 26577386
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
    Jackson LR; Peterson ED; McCoy LA; Ju C; Zettler M; Baker BA; Messenger JC; Faries DE; Effron MB; Cohen DJ; Wang TY
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792656
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Thienopyridines in Acute Coronary Syndrome.
    Goodwin MM; Desilets AR; Willett KC
    Ann Pharmacother; 2011 Feb; 45(2):207-17. PubMed ID: 21304037
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Multicenter research of bleeding risk between prasugrel and clopidogrel in Japanese patients with coronary artery disease undergoing percutaneous coronary intervention.
    Tokimasa S; Kitahara H; Nakayama T; Fujimoto Y; Shiba T; Shikama N; Nameki M; Himi T; Fukushima KI; Kobayashi Y
    Heart Vessels; 2019 Oct; 34(10):1581-1588. PubMed ID: 30944971
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Infarct size following loading with Ticagrelor/Prasugrel versus Clopidogrel in ST-segment elevation myocardial infarction.
    Sabbah M; Nepper-Christensen L; Køber L; Høfsten DE; Ahtarovski KA; Göransson C; Kyhl K; Ghotbi AA; Schoos MM; Sadjadieh G; Kelbæk H; Lønborg J; Engstrøm T
    Int J Cardiol; 2020 Sep; 314():7-12. PubMed ID: 32389767
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.
    Blin P; Dureau-Pournin C; Benichou J; Bonello L; Dallongeville J; Danchin N; Falissard B; Thomas-Delecourt F; Jové J; Lassalle R; Droz C; Moore N
    Atherosclerosis; 2019 Feb; 281():98-106. PubMed ID: 30658197
    [TBL] [Abstract][Full Text] [Related]  

  • 90. COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial.
    Vlachojannis GJ; Vogel RF; Wilschut JM; Lemmert ME; Delewi R; Diletti R; van Vliet R; van der Waarden N; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Angiolillo DJ; Krucoff MW; Van Mieghem NM; Smits PC
    Am Heart J; 2020 Jun; 224():10-16. PubMed ID: 32272255
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Pretreatment with P2Y12 inhibitors and outcome in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
    Gach O; Nyssen A; Pirlet C; Magne J; Oury C; Lancellotti P
    J Cardiovasc Med (Hagerstown); 2018 May; 19(5):234-239. PubMed ID: 29528868
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Myocardial salvage after ST-segment-elevation myocardial infarction: comparison between prasugrel and clopidogrel in the presence or absence of high-residual platelet reactivity.
    Yoshida R; Takagi K; Ishii H; Morishima I; Tanaka A; Morita Y; Kanzaki Y; Nagai H; Watanabe N; Furui K; Shibata N; Yoshioka N; Yamauchi R; Komeyama S; Sugiyama H; Tsuboi H; Murohara T
    J Nucl Cardiol; 2021 Aug; 28(4):1422-1434. PubMed ID: 31428979
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Prehospital Prasugrel Versus Ticagrelor in Real-World Patients With ST-Elevation Myocardial Infarction Referred for Primary PCI: Procedural and 30-Day Outcomes.
    Vos NS; Amoroso G; Vink MA; Maarse M; Adams R; Herrman JR; Patterson MS; van der Schaaf RJ; Slagboom T; de Winter RJ
    J Invasive Cardiol; 2018 Dec; 30(12):431-436. PubMed ID: 30318484
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction.
    Schulz S; Richardt G; Laugwitz KL; Morath T; Neudecker J; Hoppmann P; Mehran R; Gershlick AH; Tölg R; Anette Fiedler K; Abdel-Wahab M; Kufner S; Schneider S; Schunkert H; Ibrahim T; Mehilli J; Kastrati A;
    Eur Heart J; 2014 Sep; 35(34):2285-94. PubMed ID: 24816809
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Comparison of peri-procedural platelet inhibition with prasugrel versus adjunctive cilostazol to dual anti-platelet therapy in patients with ST segment elevation myocardial infarction.
    Park KH; Jeong MH; Lee KH; Sim DS; Yoon HJ; Yoon NS; Kim KH; Park HW; Hong YJ; Kim JH; Ahn Y; Cho JG; Park JC; Kang JC
    J Cardiol; 2014 Feb; 63(2):99-105. PubMed ID: 24012432
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
    Ferri LA; Morici N; Grosseto D; Tortorella G; Bossi I; Sganzerla P; Cacucci M; Sibilio G; Tondi S; Toso A; Ferrario M; Gandolfo N; Ravera A; Mariani M; Corrada E; Di Ascenzo L; Petronio AS; Cavallini C; Moffa N; De Servi S; Savonitto S
    Am Heart J; 2016 Nov; 181():101-106. PubMed ID: 27823681
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies.
    Jia M; Li Z; Chu H; Li L; Chen K
    Med Sci Monit; 2015 Apr; 21():1131-7. PubMed ID: 25893318
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: results from the HOST-REDUCE-POLYTECH-ACS trial.
    Lee KS; Park KH; Park KW; Rha SW; Hwang D; Kang J; Han JK; Yang HM; Kang HJ; Koo BK; Lee NH; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Kim SY; Shin WY; Lim HS; Park K; Kim HS
    Eur Heart J Cardiovasc Pharmacother; 2023 Apr; 9(3):262-270. PubMed ID: 36715152
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Prasugrel Use Following PCI and Associated Patient Outcomes: Insights From the National VA CART Program.
    Aggarwal V; Armstrong EJ; Liu W; Maddox TM; Ho PM; Carey E; Wang T; Sherwood M; Tsai TT; Rumsfeld JS; Bradley SM
    Clin Cardiol; 2016 Oct; 39(10):578-584. PubMed ID: 27788301
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Comparison of Ischemic and Bleeding Events Between Short-Duration Versus Long-Duration Tirofiban Regimens in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
    Denny O; Woodruff AE; Mills K; Chilbert MR
    J Cardiovasc Pharmacol; 2022 Jul; 80(1):56-61. PubMed ID: 35503989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.